The patent allowance is a modest positive for Can-Fite's IP position, but the stock remains highly speculative given the $7M market cap and reliance on future clinical data and capital raises. Monitor upcoming Phase 3 HCC data and any financing events.
Price Chart
Executive Summary
Can-Fite BioPharma announced that the Australian Patent Office allowed a patent application covering Namodenoson for treating advanced metastatic cancer, strengthening its IP portfolio for liver and pancreatic cancer programs. The patent allowance is a positive but non-financial milestone for a clinical-stage company with a $7M market cap, and the stock has historically shown high volatility on such news.
Key Facts
- Australian Patent Office allowed Patent Application No. 2021290439 titled 'Treatment of Advanced Metastatic Cancer'.
- The patent supports Namodenoson development in hepatocellular carcinoma (Phase 3) and pancreatic cancer (Phase 2a completed, Phase 2b planned).
- Namodenoson has Orphan Drug Designation in the U.S. and Europe and Fast Track Designation for HCC.
- Can-Fite is a clinical-stage biotech with no approved products and a history of losses requiring additional capital.
Financial Impact
No financial figures disclosed; patent allowance is an IP milestone with no immediate revenue impact.
Risk Factors
- Can-Fite has a history of losses and needs additional capital to fund operations, as noted in the filing.
- Clinical-stage biotech with no approved products; regulatory and clinical trial risks are high.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-077775 |
| Document: ea0297933-6k_canfite.htm | 0001213900-26-077775 |
| Document: 0001213900-26-077775-index-headers.html | 0001213900-26-077775 |
| Document: 0001213900-26-077775-index.html | 0001213900-26-077775 |
| Document: 0001213900-26-077775.txt | 0001213900-26-077775 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.95 | awaiting T+5 | — | $1.68 (−13.85%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.68 (+13.85%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.68 (+13.85%) |
Sep 14, 2026 6w ago | EFFECT | $2.30 $2.22 | ▲ +3.48% | ▲ +3.58% | $1.68 (+26.96%) |
Sep 9, 2026 6w ago | 6-K | $2.19 $2.24 | ▲ +2.28% | ▲ +3.38% | $1.68 (−23.29%) |
Sep 3, 2026 7w ago | 6-K | $2.35 $2.33 | ▼ −0.85% | ▲ +0.30% | $1.68 (−28.51%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.68 (−28.81%) |
Sep 2, 2026 7w ago | Press Release | $2.36 $2.16 | ▲ +8.47% | ▲ +7.52% | $1.68 (+28.81%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.68 (−28.81%) |
Aug 17, 2026 10w ago | 6-K | $3.58 $3.35 | ▼ −6.42% | ▼ −5.23% | $1.68 (−53.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers